

## The Ovine Cathelicidin SMAP29 Kills Ovine Respiratory Pathogens In Vitro and in an Ovine Model of Pulmonary Infection

K. A. BROGDEN,<sup>1\*</sup> V. C. KALFA,<sup>1</sup> M. R. ACKERMANN,<sup>2</sup> D. E. PALMQUIST,<sup>3</sup> P. B. McCRAY, JR.,<sup>4</sup>  
AND B. F. TACK<sup>5</sup>

*Respiratory Diseases of Livestock Research Unit, USDA Agricultural Research Service, National Animal Disease Center, Ames, Iowa 50010<sup>1</sup>; Department of Veterinary Pathology, Iowa State University, Ames, Iowa 50011<sup>2</sup>; Midwest Area, USDA Agricultural Research Service, Peoria, Illinois 61604<sup>3</sup>; and Departments of Pediatrics<sup>4</sup> and Microbiology,<sup>5</sup> College of Medicine, The University of Iowa, Iowa City, Iowa 52242*

Received 14 February 2000/Returned for modification 8 May 2000/Accepted 2 October 2000

**Cathelicidins are antimicrobial peptides from sheep (SMAP29 and SMAP34), rabbits (CAP11 and CAP18), rodents (CRAMP), and humans (FALL39, LL37, and h/CAP18). In a broth microdilution assay against nine ovine pathogens, SMAP29, SMAP34, mouse CRAMP, CAP18, CAP18<sub>31</sub>, CAP18<sub>28</sub>, CAP18<sub>22</sub>, and CAP18<sub>21a</sub> were the most active, with MICs as low as 0.6 µg/ml. Other cathelicidins were less active. In lambs with pneumonia, 0.5 mg of SMAP29 reduced the concentration of bacteria in both bronchoalveolar lavage fluid and consolidated pulmonary tissues. Hence, the antimicrobial activity of SMAP29 suggests that it has applications in the treatment of respiratory tract infections.**

Innate host defenses in the respiratory tract of sheep are currently being examined as models for airway bacterial clearance (2), cystic fibrosis (2, 3, 10–13), and *Pseudomonas aeruginosa* pneumonia (6, 7). SMAP29, a cathelicidin from sheep, is also being considered as a therapeutic agent against microbial infections (5, 9), including *P. aeruginosa* associated with chronic respiratory inflammation in cystic fibrosis patients (14). Although SMAP29 is highly effective against *P. aeruginosa* PAO1 and other common gram-positive and gram-negative organisms (14), its efficacy against a panel of pathogens originating from the same host species is unknown. Therefore, a broth microdilution assay was used to obtain both MICs and minimum bactericidal concentrations (MBCs) of SMAP29 against a panel of ovine pathogens (15, 18). SMAP34, mouse CRAMP, rat CRAMP, FALL39, FF21, CAP18, and truncated, congeners of CAP18 were included for comparison and synthesized as previously described (14). Stock solutions of peptides were diluted in 0.4% bovine serum albumin containing 0.02% acetic acid (0.16 to 80.00 µg/ml) and added to polypropylene microtiter plates (Sigma, St. Louis, Mo.); 10 mM sodium phosphate buffer (pH 7.2) with 140 mM NaCl (PBS) was added to control wells. Mueller-Hinton broth containing a 10<sup>5</sup>-CFU/ml concentration of *Mannheimia haemolytica* serovar 1 (strain 82-25), 2, or 6; *Pasteurella trehalosi* serovar 4; *Salmonella enterica* subsp. *arizonae*; ovine *Pasteurella multocida* serovar 3A (strain P-2062); *Klebsiella pneumoniae* ATCC 10031; *Corynebacterium pseudotuberculosis* ATCC 19410; *Staphylococcus aureus*; or *P. aeruginosa* PAO1 was added. Mueller-Hinton broth was added to wells containing PBS and used as the plate blank. After 24 and 48 h at 37°C, the optical density of bacterial growth was determined (Spectromax Microplate Reader; Mo-

lecular Devices Corp., Sunnyvale, Calif.). The MIC (e.g., the lowest concentration of peptide that reduced growth by more than 50% compared to control wells) and the MBC (e.g., the lowest concentration of peptide that prevented well growth) were determined.

Peptides were active against PAO1, included as a susceptible control, and these results (Tables 1 and 2) were similar to those previously reported for other assays (14). Wide ranges of activity against gram-negative bacteria were seen with mouse CRAMP (MIC, 3.3 to 15.0 µg/ml), rat CRAMP (MIC, 5.0 to 20.0 µg/ml), FALL39 (MIC, 2.1 to >20.0 µg/ml), FF21 (MIC, 3.3 to ≥20.0 µg/ml), and SMAP34 (MIC, 5.0 to 11.7 µg/ml) (Table 1). MBCs were comparable to the corresponding MICs. SMAP29 (MIC, 0.6 to 2.5 µg/ml) and CAP18 (MIC, 1.3 to 10.0 µg/ml) had the highest activities. The activity of CAP18 congeners also varied, and CAP18<sub>31</sub>, CAP18<sub>28</sub>, CAP18<sub>22</sub>, and CAP18<sub>21a</sub> were very active against gram-negative bacteria, but the others were not (Table 2). All peptides were less active against *C. pseudotuberculosis* and *S. aureus* (MIC, 10.0 to ≥20.0 µg/ml).

In CAP18, truncations of the N terminus did not adversely affect the antimicrobial activity of congeners with a complete C terminus (e.g., CAP18<sub>31</sub> and CAP18<sub>28</sub>), and truncations of the C terminus did not adversely affect the antimicrobial activity of congeners with a complete N terminus (e.g., CAP18<sub>21a</sub>). However, a severe truncation of the N terminus (e.g., CAP18<sub>26</sub>) or simultaneous truncations at both termini (e.g., CAP18<sub>21b</sub>, CAP18<sub>19</sub>, CAP18<sub>18</sub>, CAP18<sub>17</sub>, CAP18<sub>15a</sub>, and CAP18<sub>15b</sub>) decreased antimicrobial activity. Unfortunately, no central region with all of the antimicrobial activity could be identified. Instead, congeners needed to be at least 21 or more residues long to be effective. For PAO1, this number could drop to a minimum of 18 residues (e.g., CAP18<sub>18</sub>). Whether this size is related to the amphipathic structure of the peptide needed to form pores or otherwise disrupt the cytoplasmic membrane is not known.

\* Corresponding author. Mailing address: Respiratory Diseases of Livestock Research Unit, National Animal Disease Center, 2300 Dayton Ave., P.O. Box 70, Ames, IA 50010. Phone: (515) 663-7534. Fax: (515) 663-7458. E-mail: kbrogden@nadc.ars.usda.gov.

TABLE 1. Antimicrobial activities of synthetic cathelicidins against *P. aeruginosa* PAO1 and ovine pathogens

Organism	mCRAMP		rCRAMP		SMAP29		SMAP34		FALL39		FF21		CAPI8	
	MIC <sup>a</sup> (μg/ml)	MBC <sup>b</sup> (μg/ml)	MIC	MBC	MIC	MBC	MIC	MBC	MIC	MBC	MIC	MBC	MIC	MBC
<i>P. aeruginosa</i> PAO1	3.3 ± 0.7	6.7 ± 1.4	10.0 ± 0.0	20.0 ± 0.0	0.8 ± 0.2	0.8 ± 0.2	5.0 ± 0.0	11.7 ± 3.6	10.0 ± 0.0	>20.0	20.0 ± 0.0	>20.0	1.3 ± 0.0	2.5 ± 0.0
<i>M. haemolytica</i> serovar 1	15.0 ± 2.9	13.3 ± 2.7	10.0 ± 0.0	8.3 ± 1.4	0.6 ± 0.0	0.6 ± 0.0	7.5 ± 1.5	8.3 ± 1.4	5.0 ± 0.0	6.7 ± 1.4	>20.0	20.0 ± 0.0	2.5 ± 0.0	5.8 ± 1.8
<i>M. haemolytica</i> serovar 2	8.3 ± 1.4	8.3 ± 1.4	8.3 ± 1.4	8.3 ± 1.4	0.8 ± 0.2	3.8 ± 2.6	5.0 ± 0.0	5.0 ± 0.0	2.1 ± 0.3	3.3 ± 0.7	20.0 ± 0.0	>20.0	1.3 ± 0.5	5.0 ± 2.0
<i>M. haemolytica</i> serovar 6	5.0 ± 0.0	5.0 ± 0.0	10.0 ± 0.0	10.0 ± 0.0	1.3 ± 0.0	1.3 ± 0.0	5.8 ± 1.8	8.3 ± 1.4	10.0 ± 0.0	10.0 ± 0.0	20.0 ± 0.0	>20.0	5.0 ± 0.0	>20.0
<i>P. trehalosi</i> serovar 4	10.0 ± 0.0	10.0 ± 0.0	5.0 ± 0.0	5.0 ± 0.0	2.5 ± 0.0	3.3 ± 0.7	10.0 ± 0.0	10.0 ± 0.0	15.0 ± 2.9	16.7 ± 2.7	20.0 ± 0.0	20.0 ± 0.0	8.3 ± 1.4	8.3 ± 1.4
<i>S. enterica</i> subsp. <i>arizonae</i>	7.5 ± 1.5	20.0 ± 0.0	20.0 ± 0.0	>20.0	0.8 ± 0.2	1.5 ± 0.5	11.7 ± 3.6	10.0 ± 0.0	>20.0	>20.0	>20.0	>20.0	6.7 ± 1.4	11.7 ± 3.6
<i>P. multocida</i>	3.3 ± 0.7	5.0 ± 0.0	16.7 ± 2.7	20.0 ± 0.0	0.6 ± 0.0	0.6 ± 0.0	6.7 ± 1.4	6.7 ± 1.4	6.7 ± 1.4	6.7 ± 1.4	>20.0	>20.0	2.1 ± 0.3	2.1 ± 0.3
<i>K. pneumoniae</i>	3.3 ± 0.7	5.0 ± 2.0	5.0 ± 0.0	5.0 ± 0.0	0.6 ± 0.0	0.6 ± 0.0	6.7 ± 1.7	10.0 ± 4.1	13.3 ± 2.7	13.3 ± 2.7	3.3 ± 0.7	4.2 ± 0.7	2.1 ± 0.3	3.3 ± 0.7
<i>C. pseudotuberculosis</i>	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0
<i>S. aureus</i>	>20.0	>20.0	>20.0	>20.0	2.5 ± 0.0	2.5 ± 0.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	10.0 ± 0.0	16.7 ± 2.7

<sup>a</sup> MIC, the lowest concentration of peptide that reduces growth by more than 50% compared to control wells. Results are means ± standard errors of the means (three replications).

<sup>b</sup> The MBC, determined by culturing 150 μl from each of the first three wells showing no visible growth (50 μl per spot) on Trypticase soy agar containing 5% defibrinated sheep blood and incubating the plates overnight at 37°C, was the lowest concentration of peptide that prevents any growth. Results are means ± standard errors of the means (three replications).

TABLE 2. Antimicrobial activities of truncated congeners of CAPI8 against *P. aeruginosa* PAO1 and ovine pathogens

Organism	CAPI8 <sub>31</sub>		CAPI8 <sub>26</sub>		CAPI8 <sub>22</sub>		CAPI8 <sub>21a</sub>		CAPI8 <sub>21b</sub>		CAPI8 <sub>19</sub>		CAPI8 <sub>18</sub>		CAPI8 <sub>17</sub>		CAPI8 <sub>15a</sub>		CAPI8 <sub>15b</sub>		
	MIC <sup>a</sup> (μg/ml)	MBC <sup>b</sup> (μg/ml)	MIC	MBC	MIC	MBC	MIC	MBC	MIC	MBC	MIC	MBC	MIC	MBC	MIC	MBC	MIC	MBC	MIC	MBC	
<i>P. aeruginosa</i> PAO1	1.3 ± 0.0	3.3 ± 0.7	1.7 ± 0.3	4.2 ± 0.7	10.0 ± 0.0	10.0 ± 0.0	1.3 ± 0.0	1.3 ± 0.0	1.3 ± 0.0	1.3 ± 0.0	2.5 ± 0.0	2.5 ± 0.0	5.8 ± 1.8	10.0 ± 0.0	15.0 ± 2.9	13.3 ± 2.7	>20.0	>20.0	>20.0	>20.0	
<i>M. haemolytica</i> serovar 1	10.0 ± 0.0	>20.0	8.3 ± 1.4	>20.0	20.0 ± 0.0	>20.0	11.7 ± 3.6	>20.0	1.3 ± 0.0	2.5 ± 1.0	>20.0	>20.0	>20.0	>20.0	13.3 ± 2.7	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0
<i>M. haemolytica</i> serovar 2	2.9 ± 0.9	11.3 ± 5.1	4.0 ± 2.5	5.8 ± 1.8	7.5 ± 2.0	8.3 ± 1.4	2.9 ± 0.9	4.2 ± 0.7	1.3 ± 0.0	2.5 ± 1.0	7.5 ± 1.5	>20.0	2.7 ± 1.0	13.3 ± 2.7	5.8 ± 1.8	20.0 ± 0.0	6.7 ± 1.4	11.7 ± 3.6	16.7 ± 2.7	>20.0	12.5 ± 4.3
<i>M. haemolytica</i> serovar 6	13.3 ± 2.7	>20.0	20.0 ± 0.0	>20.0	>20.0	>20.0	16.7 ± 2.7	>20.0	1.3 ± 0.0	4.2 ± 2.4	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0
<i>P. trehalosi</i> serovar 4	4.2 ± 0.7	4.2 ± 0.7	1.5 ± 0.5	1.7 ± 0.3	3.3 ± 0.7	4.2 ± 0.7	4.2 ± 0.7	4.2 ± 0.7	7.5 ± 2.0	7.5 ± 2.0	20.0 ± 0.0	>20.0	13.3 ± 2.7	13.3 ± 2.7	6.7 ± 1.4	11.7 ± 3.6	10.0 ± 0.0	10 ± 0.0	>20.0	>20.0	>20.0
<i>S. enterica</i> subsp. <i>arizonae</i>	3.3 ± 0.7	13.3 ± 2.7	11.7 ± 3.6	13.3 ± 2.7	>20.0	>20.0	>20.0	16.7 ± 2.7	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0
<i>P. multocida</i>	2.5 ± 0.0	3.3 ± 0.7	3.3 ± 0.7	4.2 ± 0.7	10.0 ± 0.0	10.0 ± 0.0	13.3 ± 2.7	>20.0	5.8 ± 1.8	12.5 ± 4.3	10.0 ± 0.0	16.7 ± 2.7	20.0 ± 0.0	>20.0	>20.0	>20.0	>20.0	4.2 ± 0.7	6.7 ± 1.4	>20.0	>20.0
<i>K. pneumoniae</i>	1.3 ± 0.0	1.3 ± 0.0	0.6 ± 0.0	0.6 ± 0.0	1.7 ± 0.3	5.8 ± 1.8	2.5 ± 0.0	13.3 ± 2.7	2.5 ± 0.0	10.8 ± 4.1	1.3 ± 0.0	1.7 ± 0.3	2.5 ± 0.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0
<i>C. pseudotuberculosis</i>	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0
<i>S. aureus</i>	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0	>20.0

<sup>a</sup> MIC, the lowest concentration of peptide that reduces growth by more than 50% compared to control wells. Results are means ± standard errors of the means (three replications).

<sup>b</sup> The MBC, determined by culturing 150 μl from each of the first three wells showing no visible growth (50 μl per spot) on Trypticase soy agar containing 5% defibrinated sheep blood and incubating the plates overnight at 37°C, was the lowest concentration of peptide that prevents any growth. Results are means ± standard errors of the means (three replicates).

TABLE 3. Protective effect of SMAP29 against *M. haemolytica* in an ovine model of acute pulmonary infection

Group	Mean (SE) % lung consolidation	Mean (SE) lung lesion score <sup>a</sup>	Mean (SE) log <sub>10</sub> (1 + CFU of <i>M. haemolytica</i> /ml of BAL fluid)	Mean (SE) log <sub>10</sub> (1 + CFU of <i>M. haemolytica</i> /g of lung tissue) <sup>b</sup>
1	0.0 (0.0)	1.0 (0.0) bc	0.0 (0.0)	0.0 (0.0) b
2	0.0 (0.0)	1.3 (0.3) c	0.0 (0.0)	0.0 (0.0) b
3	8.8 (2.6)	6.1 (0.9) a	2.3 (0.8)	5.1 (1.0) a
4	5.6 (2.3)	5.0 (1.3) ab	0.9 (0.4)	3.7 (0.9) ab

<sup>a</sup> Means sharing the same letter(s) within the column are not significantly different from one another based on Duncan's multiple-range test performed at the 0.05 level.

<sup>b</sup> Means sharing the same letter(s) within the column are not significantly different from one another based on Duncan's multiple-range test performed at the 0.01 level.

The high activity of SMAP29 in these assays suggested that it might also be effective in vivo. To demonstrate this, 15 lambs, approximately 60 to 70 lb, were lightly sedated for bronchoscopy as previously described (1). Inocula were placed into the dorsum of the caudal portion of the cranial lobe of the right lung (pulmonary deposition site) in each animal. Two lambs in group 1 and three lambs in group 2 received 10 ml of PBS with 0.25 mg of purified ovine pulmonary surfactant per ml (PBS-PS). Five lambs in group 3 and five lambs in group 4 received 10 ml of *M. haemolytica* ( $2.5 \times 10^8$  CFU/ml in PBS-PS). PBS-PS was used as a diluent to decrease atelectasis and facilitate pulmonary spreading (4, 17). At 24 h postinoculation, lambs in group 1 and group 3 received an additional 10 ml of PBS-PS at the same deposition site. Lambs in group 2 received 10 ml of PBS-PS with 100  $\mu$ g of SMAP/ml, and those in group 4 received 10 ml of PBS-PS with 50  $\mu$ g of SMAP29/ml.

At 48 h postinoculation, all lambs were euthanized, their lungs were evaluated grossly, and total lung involvement was calculated as previously described (1, 16). Bronchoalveolar lavage (BAL) fluids and consolidated lung tissue were collected for quantitative bacteriological culture, determination of total leukocyte counts, and histopathological examination. The extents of lymphocytic and/or neutrophilic infiltration, necrosis, and collapse were scored as previously described (1), with a maximum score of 4 for each category. The concentrations of *M. haemolytica* in pulmonary tissues and fluids were transformed [ $\log_{10}(X + 1)$ ], and differences among groups was assessed by one-way analyses of variance. When an analysis of variance resulted in a significant *F*-test statistic, indicating group differences, Duncan's multiple-range test was used as the multiple comparison procedure for detecting pairwise differences among the treatment group means.

The lungs of lambs in groups 1 and 2 were free of gross lesions and histopathology (Table 3). BAL fluids contained means of  $0.4 \times 10^6$  and  $0.9 \times 10^6$  leukocytes/ml, respectively. Bronchioles and surrounding alveoli contained minimal to mild infiltrates of lymphocytes in the bronchiolar wall, but there was no acute inflammatory response in the bronchioles or alveoli.

The lungs of lambs in group 3 had extensive lesions characterized by focal areas of consolidation with hemorrhage and necrosis. BAL fluids contained a mean of  $3.3 \times 10^6$  leukocytes/ml. There were minimal multifocal lymphocytic peribronchio-

lar infiltrates, mild to suppurative bronchitis and/or pneumonia, and minimal to moderate necrosis, hemorrhage, and collapse. Four of five lambs had *M. haemolytica* in BAL fluid ( $2.3 \log_{10}$  CFU/ml), and all five lambs had organisms in consolidated pulmonary tissues ( $5.1 \log_{10}$  CFU/g) collected from the deposition site. (Table 3).

The lesions in the lungs of lambs in group 4 were not as severe, and BAL fluids contained a mean of  $4.9 \times 10^6$  leukocytes/ml. Sections of bronchioles and surrounding alveoli showed moderate numbers of lymphocytes in the bronchiolar wall but no acute inflammatory response. Three of five lambs had *M. haemolytica* in the BAL fluid ( $0.9 \log_{10}$  CFU/ml), and all of the lambs had lesser numbers of organisms in consolidated pulmonary tissues ( $3.7 \log_{10}$  CFU/g) collected from the deposition site.

Previously, prevention or treatment of respiratory infections with cathelicidins has not been fruitful. For example, CAP18 mixed with *P. aeruginosa* prior to intratracheal instillation in mice significantly reduced pulmonary injury but did not reduce the number of bacteria that had been instilled, nor did it improve the survival of the infected mice (8). Interestingly, CAP18 alone induced edema, suggesting that it had some pulmonary toxicity (8). To eliminate these species differences within the model, we established a homologous ovine model of acute pneumonia using ovine SMAP29 against the ovine respiratory pathogen *M. haemolytica*. SMAP29 alone was well tolerated (group 2), and the 1.0-mg dose (twice the treatment dose in group 4) did not induce any significant gross pathology, histopathology, or inflammatory cell filtrates in BAL fluid. Also, lambs treated with only a single dose of SMAP29 had substantially lower gross pulmonary lesion scores, histopathological lesion scores, and concentrations of *M. haemolytica* in BAL fluids and consolidated pulmonary tissues than untreated lambs. Further studies will determine the optimal doses and intervals of SMAP29 therapy.

We thank Gwen Laird and Abby Lozano for technical assistance.

This work was supported by the Cystic Fibrosis Foundation (BROGDE97Z, McCray 97ZO). P.B.M. is the recipient of a Career Development Award from the American Lung Association.

#### REFERENCES

- Brogden, K. A., M. R. Ackermann, and B. M. DeBey. 1995. *Pasteurella haemolytica* lipopolysaccharide-associated protein induces pulmonary inflammation after bronchoscopic deposition in calves and sheep. *Infect. Immun.* **63**:3595–3599.
- Gerson, C., J. Sabater, M. Scuri, A. Torbati, R. Coffey, J. W. Abraham, I. Lauredo, R. Forteza, A. Wanner, M. Salathe, W. M. Abraham, and G. E. Conner. 2000. The lactoperoxidase system functions in bacterial clearance of airways. *Am. J. Respir. Cell Mol. Biol.* **22**:665–671.
- Harris, A. 1997. Towards an ovine model of cystic fibrosis. *Hum. Mol. Gen.* **6**:2191–2193.
- Katkin, J. P., R. C. Husser, C. Langston, and S. E. Welty. 1997. Exogenous surfactant enhances the delivery of recombinant adenoviral vectors to the lung. *Hum. Gene Ther.* **8**:171–176.
- Mahoney, M. M., A. Y. Lee, D. J. Brezinski-Caliguri, and K. M. Huttner. 1995. Molecular analysis of the sheep cathelin family reveals a novel antimicrobial peptide. *FEBS Lett.* **377**:519–522.
- Patterson, G. A., and T. R. J. Todd. 1982. A large animal model of *Pseudomonas aeruginosa*. *J. Surg. Res.* **33**:214–219.
- Pittet, J. F., M. A. Matthay, G. Pier, M. Grady, and J. P. Wiener-Kronish. 1993. *Pseudomonas aeruginosa*-induced lung and pleural injury in sheep. Differential protective effect of circulating versus alveolar immunoglobulin G antibody. *J. Clin. Invest.* **92**:1221–1228.
- Sawa, T., K. Kurahashi, M. Ohara, M. A. Gropper, V. Doshi, J. W. Larrick, and J. P. Wiener-Kronish. 1998. Evaluation of antimicrobial and lipopolysaccharide-neutralizing effects of a synthetic CAP18 fragment against

- Pseudomonas aeruginosa* in a mouse model. *Antimicrob. Agents Chemother.* **42**:3269–3275.
9. **Skerlavaj, B., M. Benincasa, A. Risso, M. Zanetti, and R. Gennaro.** 1999. SMAP-29: a potent antibacterial and antifungal peptide from sheep leukocytes. *FEBS Lett.* **463**:58–62.
  10. **Tebbutt, S. J., M. F. Broom, T. C. van Stijn, G. W. Montgomery, and D. F. Hill.** 1996. Genetic and physical mapping of the ovine cystic fibrosis gene. *Cytogenet. Cell Genet.* **74**:245–247.
  11. **Tebbutt, S. J., A. Harris, and D. F. Hill.** 1996. An ovine CFTR variant as a putative cystic fibrosis causing mutation. *J. Med. Genet.* **33**:623–624.
  12. **Tebbutt, S. J., M. B. Lakeman, J. C. Wilson-Wheeler, and D. F. Hill.** 1998. Genetic variation within the ovine cystic fibrosis transmembrane conductance regulator gene. *Mutat. Res.* **382**:93–98.
  13. **Tebbutt, S. J., C. J. Wardle, D. F. Hill, and A. Harris.** 1995. Molecular analysis of the ovine cystic fibrosis transmembrane conductance regulator gene. *Proc. Natl. Acad. Sci. USA* **92**:2293–2297.
  14. **Travis, S. M., N. N. Anderson, W. R. Forsyth, C. Espiritu, B. D. Conway, E. P. Greenberg, P. B. McCray, Jr., R. I. Lehrer, M. J. Welsh, and B. F. Tack.** 2000. Bactericidal activity of mammalian cathelicidin-derived peptides. *Infect. Immun.* **68**:2748–2755.
  15. **Turner, J., Y. Cho, N. N. Dinh, A. J. Waring, and R. I. Lehrer.** 1998. Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. *Antimicrob. Agents Chemother.* **42**:2206–2214.
  16. **Valero, G., M. R. Alley, and B. W. Manktelow.** 1992. Visual assessment of pneumonic area in ovine lungs. *N.Z. Vet. J.* **40**:79–80.
  17. **van't Veen, A., J. W. Mouton, D. Gommers, and B. Lachmann.** 1996. Pulmonary surfactant as vehicle for intratracheally instilled tobramycin in mice infected with *Klebsiella pneumoniae*. *Br. J. Pharmacol.* **119**:1145–1148.
  18. **Wu, M., and R. E. Hancock.** 1999. Interaction of the cyclic antimicrobial cationic peptide bactenecin with the outer and cytoplasmic membrane. *J. Biol. Chem.* **274**:29–35.